Overestimation of the effect size in group sequential trials

Area of Science:

• Clinical Trials Methodology
• Biostatistics
• Oncology Research

Background:

• Group sequential designs (GSDs) are widely used in oncology clinical trials for interim data monitoring and early stopping.
• While ethically beneficial, GSDs are known to overestimate treatment effect sizes during early interim analyses.
• This overestimation can lead to imprecise drug benefit information for clinicians and patients.

Purpose of the Study:

• To provide a clear graphical explanation for the phenomenon of treatment effect overestimation in group sequential designs.
• To enhance understanding of the causes and consequences of this overestimation in clinical trial practice.
• To address concerns regarding effect overestimation, particularly with subjective endpoints like progression-free survival in oncology.

Main Methods:

• Graphical explanation of the statistical properties of group sequential designs.
• Analysis of treatment effect estimation at interim analysis points within GSDs.
• Focus on the implications for primary endpoints in Phase III oncology trials, such as progression-free survival.

Main Results:

• Demonstration of how interim analyses in GSDs can lead to inflated estimates of treatment effect size.
• Identification of the statistical underpinnings contributing to this overestimation phenomenon.
• Highlighting the specific concerns in oncology due to the increasing use of progression-free survival as a primary endpoint.

Conclusions:

• Group sequential designs, while valuable, inherently possess a tendency to overestimate treatment effects at interim analyses.
• Understanding the graphical basis of this overestimation is crucial for accurate interpretation of trial results.
• The findings are particularly relevant for oncology trials using progression-free survival, emphasizing the need for careful interpretation of early efficacy signals.